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Abstract: Treatment with erythropoietin (Epo) in experimental autoimmune encephalomyelitis (EAE),
the rodent model of multiple sclerosis (MS), has consistently been shown to ameliorate disease progression
and improve overall outcome. The effect has been attributed to modulation of the immune response
and/or preservation of the central nervous system (CNS) tissue integrity. It remains unclear, however, if
(a) Epo acts primarily in the CNS or the periphery and if (b) Epo’s beneficial effect in EAE is mainly due
to maintaining CNS tissue integrity or to modulation of the immune response. If Epo acts primarily by
modulating the immune system, where is this modulation required? In the periphery, the CNS or both?
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Abstract
Background: Treatment with erythropoietin (Epo) in experimental autoimmune encephalomyelitis (EAE), the rodent
model of multiple sclerosis (MS), has consistently been shown to ameliorate disease progression and improve
overall outcome. The effect has been attributed to modulation of the immune response and/or preservation of the
central nervous system (CNS) tissue integrity. It remains unclear, however, if (a) Epo acts primarily in the CNS or the
periphery and if (b) Epo’s beneficial effect in EAE is mainly due to maintaining CNS tissue integrity or to modulation
of the immune response. If Epo acts primarily by modulating the immune system, where is this modulation
required? In the periphery, the CNS or both?
Methods: To address these questions, we used two well-characterized transgenic mouse strains that constitutively
overexpress recombinant human Epo (rhEpo) either systemically (tg6) or in CNS only (tg21) in a MOG-induced EAE
model. We assessed clinical severity, disease progression, immunomodulation, and CNS tissue integrity, including
neuronal survival.
Results: Although disease onset remained unaffected, EAE progression was alleviated in transgenic animals
compared to controls with both lines performing equally well showing that expression of Epo in the periphery is
not required; Epo expression in the CNS is sufficient. Immunomodulation was observed in both strains but
surprisingly the profile of modulation differed substantially between strains. Modulation in the tg21 strain was
limited to a reduction in macrophages in the CNS, with no peripheral immunomodulatory effects observed. In
contrast, in the tg6 strain, macrophages were upregulated in the CNS, and, in the periphery of this strain, T cells
and macrophages were downregulated. The lack of a consistent immunomodulatory profile across both transgenic
species suggests that immunomodulation by Epo is unlikely to be the primary mechanism driving amelioration of
EAE. Finally, CNS tissue integrity was affected in all strains. Although myelin appeared equally damaged in all strains,
neuronal survival was significantly improved in the spinal cord of tg21 mice, indicating that Epo may ameliorate
EAE predominantly by protecting neurons.
Conclusions: Our data suggests that moderate elevated brain Epo levels provide clinically significant
neuroprotection in EAE without modulation of the immune response making a significant contribution.
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Background
Multiple sclerosis (MS) results in long-term disability
and reduced life expectancy. A chronic autoimmune dis-
ease of the CNS, MS is classically characterized by CNS
inflammation, widespread demyelination, and damage of
oligodendrocytes and neurons. Substantial irreversible
axonal damage and neuronal cell death are thought to
be an essential cause of non-remitting clinical disability
in primary and secondary progressive MS. So far, no
clinically effective therapy has been established to pre-
vent axonal and neuronal damage in this neuroinflam-
matory disease, and despite much research,
understanding of the etiology and pathogenesis of this
condition remains limited.
Erythropoietin (Epo) is a hematopoietic growth factor
that circulates in plasma and primarily controls the
oxygen-carrying capacity of the blood [1]. Epo has an
established safety profile for clinical use and has been
extensively employed to increase red blood cell count
during treatment of anemia [2] thereby avoiding the re-
quirement for blood transfusions in dialysis and cancer
patients [3, 4]. Originally believed to play a role re-
stricted to stimulation of early erythroid precursor pro-
liferation and differentiation, in recent years Epo has
evolved into a promising candidate for neuroprotective
approaches to diverse brain diseases [5–8], such as epi-
lepsy [9], Parkinson’s disease [10], Alzheimer’s disease
[11, 12], traumatic brain injury [13], ischemia [14–16],
and diabetic neuropathy [17, 18]. Epo can cross the
blood-brain barrier and is secreted within the CNS by
astrocytes [19–21]. Under normal conditions, the Epo
receptor (EpoR) is mainly expressed by neurons [22] but
during insults such as hypoxia, ischemia, and trauma all
cells including neurons, microglia, and astrocytes [19,
23, 24] are able to upregulate the Epo signaling cascade
eliciting both autocrine and paracrine effects [18]. Al-
though the exact mechanisms behind Epo’s neuroprotec-
tive effects are not well understood, its putative anti-
inflammatory actions and enhancement of survival sig-
nals probably play a key role [7, 25–29].
To date, a substantial number of publications have
shown that Epo and Epo derivatives have significant bene-
ficial potential in various rodent models of MS [25, 27,
30–38]. Despite using significantly different treatment
protocols, remarkably and indeed encouragingly, all the
studies recorded a significant reduction in disease severity.
As treatment of MS will inevitably need to be long
term, a significant limitation of most of the above stud-
ies was the relatively short duration of Epo treatment,
varying from 7 to 14 days only, to circumvent detrimen-
tally high increases in hematocrit. In this respect, the re-
cent studies with Epo derivatives such as ARA290 [38],
JM-4 [27], and Epobis [39] are encouraging, showing
that, at least to some extent, the immunomodulatory
effects of Epo can be separated from its erythropoietic
properties in animal models of MS.
Taken together, these animal studies indicate that treat-
ment of Epo and/or derivatives of Epo may be beneficial
in MS, and indeed the first trials in humans were encour-
aging. The first proof-of-principle exploratory open label
study (phase I/IIa) of recombinant human Epo (rhEPO)
treatment in patients with chronic progressive MS,
showed a significant improvement in patient clinical and
electrophysiological motor functions that persisted for 3
to 6 months after cessation of Epo application. Import-
antly, the treatment protocols used had no adverse effects
but blood-lettings to reduce hematocrit were required
[40]. More recently, another randomized double-blind
pilot study combined Epo with methylprednisolone in se-
vere motor relapsing-remitting MS patients. Improvement
in maximal distance walking was observed in the Epo
group after 2 months and MRI data analysis showed a sig-
nificant reduction in the number of T2WI lesions [41].
Despite these encouraging results, in the recent large-
scale phase 2 trial of Epo in 52 patients with primary or
secondary progressive MS, no beneficial effects of high-
dose Epo treatment were detected [42]. No difference in
the primary outcome, a composite measure of maximum
gait distance, hand dexterity, and cognition from baseline
to 24 weeks, between the EPO and the placebo group of
the intention-to-treat populations, was observed and none
of the secondary outcomes, neither clinical nor magnetic
resonance imaging (MRI) measures, showed any signifi-
cant differences. Although this study provides class 2 evi-
dence that treatment with high-dose EPO is not an
effective treatment in patients with progressive MS, the
question if Epo treatment is effective in relapsing-
remitting MS (RR-MS) patients remains open. Especially
because the immunomodulatory properties of Epo are
more likely to have an effect in the immune response-
driven RR-MS stage rather than in the more immune qui-
escence progressive MS stages.
In short, to date, most studies indicate beneficial ef-
fects of Epo treatment in MS and EAE. However, there
is very little consensus on its precise mechanism of ac-
tion. Reported effects on the immune system are incon-
sistent between the different studies and direct
neuroprotective effects of Epo in MS or EAE have not
been convincingly established either.
Clearly better mechanistic insight will potentially allow
(1) a more “mechanism of action”-focused approach to
treatment of MS patients with Epo or its derivatives and
(2) beneficial effects to be dissociated from possible
negative side effects of Epo treatment, such as sustained
elevated hematocrit levels, tumor growth, or prolonged
suppression of inflammatory responses.
We performed a detailed study to analyze the patho-
logical elements of EAE while distinguishing between
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Epo effects on the CNS directly versus peripheral effects
influencing the immune response. We used two well-
characterized transgenic mouse strains, called tg6 and
tg21, that constitutively overexpress human Epo system-
ically (CNS and periphery, tg6) or in CNS only (tg21)
[43–45]. We studied whether Epo acts directly on cells
of the CNS or has a more systemic role in modulation
of the autoimmune response in EAE. We assessed
whether peripheral effects of Epo, such as increased
erythropoiesis and modulation of the immune response,
influence disease outcome.
Our data shows that Epo’s primary beneficial effect in
EAE resides in the CNS, most likely by protecting neu-
rons during EAE progression, and that immune modula-




All experiments were performed in accordance with Swiss
animal protection laws and Zürich University institutional
guidelines. The transgenic mouse line was generated by
pronuclear injection of the full length human Epo cDNA
driven by the human platelet-derived growth factor (PDGF)
B-chain promoter and has been previously described [46,
47]. Two mice lines were generated; TgN(PDGFBE-
PO)321ZbZ (termed tg6) displayed 10–12-fold increased
plasma and brain levels of Epo leading to hematocrit values
of up to 0.9. The line was bred by mating hemizygous
males to wild type (wt) C57BL/6 females and half the off-
spring were hemizygous for the transgene and half were wt
thus serving as controls. The other transgenic line
TgN(PDGFBEPO)322ZbZ (termed Tg21), bred to homozy-
gosity, showed a fourfold increase of Epo levels in brain but
not in blood plasma [43, 48]. Transgenic homozygous mice
were backcrossed with C57Bl/6 mice for more than six gen-
erations to obtain wt littermates. In this study, male and fe-
male mice were used at 8–12 weeks of age.
Antibodies
For flow cytometry, the following antibodies were used:
CD3 (biotin), CD4 (PE), CD8 (FITC), CD11b (biotin),
B220 (biotin) and Gr1 (FITC), which were obtained from
BD PharMingen and F4/80 (FITC) from Serotec. CD11b
(unlabeled), CD16/32 (Fc block), and CD45 (APC) were
purchased from Biolegend and CD11c (clone N418, PE)
from Caltag. The following antibodies were used for
Western blotting and immunohistochemistry: anti-MBP,
anti-smi35, anti-smi32 (1:1000, Sternen monoclonals),
anti-neurofilament (Zymed, San Francisco, USA), anti-
GFAP and anti-β-actin (Sigma). Secondary antibodies
used were anti-rabbit HRP (Pierce), anti-rat Alexa 488
and anti-rabbit Alexa 594 (Molecular Probes/Invitrogen)
and Streptavidin-APC-Cy7 (Biolegend).
Induction of EAE
Mice were injected with 100 μg MOG35–55 (Anawa,
Switzerland) in 200 μl PBS/CFA (DIFCO, USA) (1:1) sub-
cutaneously on the right flank and with 300 ng Pertussis
toxin (List Biological Laboratories, USA) intraperitoneal
(i.p.) on day 0, followed by a boost of 300 ng Pertussis
toxin at day 2 and 100 μg MOG35–55 in CFA into the left
flank on day 7. The scoring of clinical symptoms was per-
formed daily from day 7 onwards as described previously
[49–51]. In all figures, preclinical, peak, early, and late (re-
mission) refer to days 7, 17 ± 2, 24, and 30 ± 3 days post-
immunization (p.i.) respectively.
Cytokine multiplex
Spinal cord lysates were prepared using the Bio-Plex
Pro™ Mouse Cytokine 23-plex Assay from BioRad ac-
cording to the manufacturer’s instructions. Briefly,
isolated spinal cords were washed with cell wash buf-
fer, transferred to a 2-ml tissue grinder containing
500 μl of lysing solution and homogenized on ice.
After a freeze cycle at − 70 °C, sonification on ice
and centrifugation at 4500×g for 4 min, the super-
natant was collected and the protein concentration
determined. All samples were diluted to a final con-
centration of 0.5 mg/ml and stored at − 20 °C. Sam-
ples were analyzed on a Bio-Plex 200 system.
Isolation of CNS mononuclear cells, lymphocytes, and
splenocytes
CNS mononuclear cells were isolated as described previ-
ously [50]. Briefly, brains and spinal cords of animals
perfused with Hanks’ balanced salt solution (HBSS) were
minced with a scalpel blade and digested for 30′ at 37 °
C in HBSS containing 50 mg/ml DNase I and 100 mg/
ml Collagenase/Dispase (Roche). The digestion was
quenched on ice and passed through a 100-μm nylon
mesh (BD Biosciences) and centrifuged after which the
pellet was resuspended in 30% Percoll (Sigma). The gra-
dient was centrifuged at 29,000×g for 30 min at 4 °C
(Kontron Instruments, Germany). The top layer contain-
ing myelin was removed by aspiration, and the inter-
phase containing mononuclear cells was collected,
diluted threefold with HBSS, collected by centrifugation
at 300×g and resuspended in an appropriate volume of
FACS buffer (2% FCS, 5 mM EDTA, 0.01% NaN3) in
phosphate buffered saline (PBS). To isolate lymphocytes,
inguinal lymph nodes were mashed through a 100-μm
cell strainer, washed with HBBS and resuspended in
FACS buffer. To obtain splenocytes, spleens were
mashed through a 100-μm cell strainer followed by lysis
of erythrocytes in ACK buffer (155 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA, pH 7.2), several washes with
HBBS and resuspension in FACS buffer.
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Flow cytometric analysis
Flow cytometric analysis was performed as described pre-
viously [50, 51]. Prior to staining with the appropriate
antibodies, Fc receptors were blocked by incubation with
anti-mouse CD16/32 (Fc block). 7-Amino-actinomycin D
(7-AAD) was used to exclude non-viable cells. All flow cy-
tometric data was obtained with a CyFlow flow cytometer
(Partec, Germany) and data analysis was performed with
FlowJo software. Infiltrating mononuclear cells were dis-
tinguished from CNS-resident microglia (CD45int/CD11b
+/F4/80+) based on high CD45 expression. Within this
population, the following cell types were distinguished
using gating as indicated between brackets: CD4 T cells
(CD3+/CD4+), CD8 T cells (CD3+/CD8+), T regs (regula-
tory T cells; CD4+/CD25+/FoxP3+), DCs (dendritic cells;
CD11c+/B220−/Gr1−), pDCs (plasmacytoid DCs; CD11c
+/B220+/Gr1+), B cells (CD11c−/B220+/Gr1−), macro-
phages (CD11c−/CD11b+/F4/80+).
Quantitative polymerase chain reaction (qPCR)
Total RNA from cultured cells was extracted using the
NucleoSpin-RNA II kit (Macherey-Nagel, Switzerland).
RNA from mouse tissues was extracted by homogenization
in TRIzol (Invitrogen) according to the manufacturer’s in-
structions. RNA was reverse-transcribed using random
hexamers and AMV reverse transcriptase (Promega). The
cDNA equivalent to 50 ng of total RNA was PCR-amplified
in an ABI PRISM 7700 detection system using TaqMan
Universal PCR Master Mix (PE-Applied Biosystems) and
quantified using the 2−ΔΔCT method using 18s rRNA as a
housekeeping gene. Relative RNA levels are expressed as x-
fold variations compared to control. Primers and probes for
Taqman analysis for IL-1β, IL-2, IL-6, IL-10, IL-17, IL-23,
TNFα, IFNγ, and TGFβ1 were purchased from Applied
Biosystems.
Epo radioimmuneassay (RIA)
Quantitation of Epo was performed on blood plasma as
well as brain and spinal cord tissue lysate samples using
EPO-Trac™ 125I RIA Kit according to manufacturer’s in-
structions (Diasorin, USA). Bound tracer was measured
using a gamma counter (Gamma counter 670, Kontron,
Germany).
Western blotting
Experiments were carried out on brain lysates from trans-
genic and littermate controls. Tissue was homogenized in
lysis buffer using a sterile dounce homogenizer. Samples
were then centrifuged at 13,000 rpm at 4 °C for 10 min,
supernatant extracted and stored at − 20 °C. Fifty micro-
grams of protein was run on a 10% SDS PAGE, transferred
to a nitrocellulose membrane, blocked in 5% non-fat milk,
and then incubated with primary antibodies overnight at
4 °C or 2 h at room temperature. After washing and
incubation for 1 h with a horseradish peroxidase-
conjugated secondary antibody, chemiluminescent detec-
tion was carried out. Normalization was achieved by
reprobing filters with β-actin. Blot quantification was per-
formed using ImageJ software (NIH, Bethesda, USA).
Immunohistochemistry and histology
Mouse spinal cords were dissected and immediately fro-
zen in liquid nitrogen. Using a cryostat, 10-μM sections
were cut, fixed with 4% paraformaldehyde in PBS (pH
7.4) for 5 min at room temperature, then permeabilized
in 0.1% Triton X-100 for 2 min and blocked with 4%
normal goat serum. Sections were then incubated with
primary antibodies overnight at 4 °C. Secondary anti-
bodies were then applied for 2 h at room temperature
followed by counterstaining with DAPI. To determine
axonal damage and loss, cryostat serial sections from
thoracic and lumbar spinal cord were stained for neuro-
filament, SMI32, and SMI35. Images were captured
using a Zeiss Axiovert 200 M fluorescence microscope
with an attached CCD camera. Five images were cap-
tured from individual brain sections per animal. Images
were processed and quantified using NIH ImageJ soft-
ware. After manual selection of the area of interest, the
image was inverted and converted to binary and the
number of axons analyzed using the particle count op-
tion. To assess the degree of demyelination, spinal cords
were removed, fixed in 4% buffered formalin, and em-
bedded in paraffin before staining with hematoxylin
eosin (H&E) and luxol fast blue (LFB) as described re-
cently [51]. At least four animals per group and four im-
ages per animal were analyzed.
Statistical analysis
Graphic and statistical analyses were performed using
Microsoft Excel and Prism software. Western blot data
and axonal damage was quantified using NIH ImageJ
software. Data are presented as mean ± standard error
of the mean (SEM). Statistical significance was calcu-
lated using Student’s t test or two-way ANOVA plus
Bonferroni post hoc test as indicated in figure legends.
*p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.
Results
Epo mRNA is elevated in EAE spinal cord
In the inflamed CNS, endogenous Epo has been found to be
elevated possibly in direct response to insult [18, 22, 25, 52].
This rise in Epo expression is speculated to have neuropro-
tective properties and may have a palliating effect on neuro-
inflammation. We also observed Epo induction during
MOG-induced EAE progression in C57Bl6, a model system
of severe neuroinflammation (Fig. 1a). Examination of Epo
expression in the spinal cord by quantitative RT-PCR
showed that at peak disease on day 17 post-immunization
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(p.i.) Epo mRNA levels are significantly elevated (approxi-
mately 2.5-fold). In the early remission phase (d24 p.i.), Epo
mRNA is still elevated but then declines at late-stage EAE
(d30 p.i.). At this late stage, Epo mRNA levels are not signifi-
cantly different from those of naïve or immunized mice be-
fore any clinical signs appear (preclin. d7 p.i.; Fig. 1a).
Moderate rhEpo expression in the CNS is sufficient to
provide amelioration from EAE
Several studies have shown that, in general, supplement-
ing mice or rats with exogenous Epo reduces the overall
severity of EAE [25, 26, 30–34, 36, 37]. It is currently
unclear, however, if this is due to modulation of the per-
ipheral immune response, alleviation of neuroinflamma-
tion, or the result of neuroprotection solely in the CNS.
Therefore, we subjected tg6 mice that express rhEpo at
high levels in both the periphery and the CNS, and tg21
mice in which rhEpo expression is moderate and limited
to the CNS [43, 46], as well as littermate control wt mice
to EAE and monitored disease progression (Fig. 1b) and
weight loss (Fig. 1c). Notably, tg6 mice suffer from sig-
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Fig. 1 EAE disease progression and weight loss in wt, tg6 (rhEpo expression in CNS and periphery), and tg21 mice (rhEpo expression in CNS
only). a Quantitative RT-PCR analysis of Epo mRNA expression in spinal cord at different EAE stages in wt mice. n = 3, Student’s t tests versus
naïve. b EAE progression monitored in mice immunized with MOG using a standard method that scores the degree of paralysis on a 1 to 5 scale.
c Weight fluctuations of the same group of mice during disease. Start weight was set to 100%. In all strains, the onset of weight loss correlates
well with the onset of disability whereas the partial recovery from disability coincides with a gain in weight. d Mean accumulative clinical score. e
Hematocrit measurements at the end of experiment. Combined results of six independent experiments are shown. n = 39 tg21, 25 tg6, and 75
wt (b, c) ANOVA, *significant difference wt versus tg21 (p < 0.05 or more), + significant difference wt versus tg6 (p < 0.05 or more), # significant
difference tg21 versus tg6 (p < 0.05 or more); (d, e) t test versus wt *p < 0.05, ***p < 0.001
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Epo concentrations, while hematocrit of tg21 mice is at
wt levels (Fig. 1e). After immunization with MOG, onset
of EAE occurred around the same day in all strains
(Fig. 1b, d8 p.i.) and the initial increase in EAE severity
progressed at a comparable rate. In tg21 mice, EAE
peaked at d15 p.i. with an average score of 2.12, whereas
in tg6 mice the disease peaked at d17 p.i. with an almost
identical score of 2.14. In contrast, EAE severity in wt
animals rose to an average score of 2.72 at d17 p.i. Aver-
age scores differed significantly between tg6 and wt mice
from dpi 13 onwards and between tg21 and wt mice
from d15 p.i. onwards (p < 0.05). Disease scores between
tg6 and tg21 showed a significant difference only on d14
p.i. (p < 0.05). These data and the significantly higher
mean accumulative clinical score in wt mice (Fig. 1d),
reveal a comparable amelioration of EAE in tg6 and tg21
mice. Weight loss monitored over the course of disease
correlated well with disease progression in all strains
(Fig. 1c). The lowest average weight was recorded in all
strains on d15 p.i. Control mice lost 17% of their initial
weight recorded on d7 p.i. and tg21 mice lost a compar-
able 14%. Remarkably, tg6 mice displayed only minor
weight loss (6%). Two-way ANOVA analysis shows that
wt mice lost significantly more weight than both trans-
genic strains, although tg21 mice did lose significantly
more weight than tg6 mice.
Since disruption of the blood-brain barrier can be an-
ticipated in EAE, we performed several control experi-
ments measuring rhEpo protein levels in serum and
CNS lysates (Additional file 1: Figure S1). Importantly,
in tg21 mice, rhEpo protein remains confined to the
CNS during EAE, being detected in brain and spinal
cord lysates at constant concentrations (Additional file
1: Figure S1C and B, respectively) but not in serum
(Additional file 1: Figure S1A), thus excluding peripheral
effects of rhEpo on EAE progression due to blood-brain
barrier (BBB) leakage. Curiously, in tg6 mice, reduced
rhEpo serum levels were observed at peak disease (Add-
itional file 1: Figure S1A) although CNS levels stayed
constant (Additional file 1: Figure S1B and C). All sam-
ples emphasized the six- to eightfold higher rhEpo ex-
pression levels in tg6 mice compared to tg21 mice
(Additional file 1: Figure 1).
Taken together, these data strongly indicate that a
modest increase in Epo concentrations restricted to the
CNS, as found in tg21 mice, is sufficient to confer the
maximum alleviation from EAE. Higher Epo levels in
the periphery and/or CNS, as found in tg6 mice, do not
augment alleviation.
Cytokine expression in the CNS at peak EAE is altered in
tg6 but not in tg21 mice
During both MS and EAE, the CNS is subjected to a
steep increase in the concentration of disease-mediating
pro-inflammatory cytokines followed by a wave of dis-
ease alleviating anti-inflammatory cytokines at later
stages. Since Epo could potentially trigger changes in the
CNS expression of cytokines at all EAE stages, we ana-
lyzed cytokine mRNA expression in the different strains
in naïve mice and EAE-diseased mice at peak and late-
stage disease (Fig. 2a). Real-time quantitative PCR
showed that cytokine expression in the CNS is compar-
able in all strains at all EAE stages with the notable ex-
ception of IL-2, which is found at lower concentrations
in tg6 animals at peak EAE, and IL-23 which is elevated
in naïve tg6 animals. In addition, we analyzed CNS pro-
tein expression of a broader panel of cytokines and che-
mokines at late-stage EAE by multiplex (Fig. 2b). With
the notable exception of IL-9 protein that was found at
threefold higher concentrations in tg6 mice, no signifi-
cant differences were detected in any of the other cyto-
kines or chemokines. Notably, the comparable cytokine
and chemokine profiles in wt and tg21 mice suggests
that, despite the differences observed in tg6 mice, Epo
does not ameliorate EAE by modulating cytokine and/or
chemokine expression.
Leukocyte populations are differentially affected in tg6
versus tg21 mice during EAE
Since the expression of rhEpo may modulate the cellular
inflammatory response, we conducted an in-depth ana-
lysis of different leukocyte subsets over the course of
EAE in the CNS, spleen and inguinal lymph nodes (LN)
by flow cytometry (Fig. 3 and Additional file 2: Table
S1). Importantly, in the CNS at peak EAE, no significant
differences were detected between the different mice
strains in any of the leukocyte populations investigated
with the notable exception of the macrophage popula-
tion, which was significantly decreased in tg21 mice and,
paradoxically, increased in tg6 mice as compared to wt
mice (Fig. 3a). In the tg6, periphery differences were also
observed; in the LN and spleen, both the CD4 and CD8
T cell populations were reduced (Fig. 3b, c). In addition,
the macrophage population was significantly smaller in
the spleen and the dendritic population marginally up-
regulated (Fig. 3b).
At late-stage EAE, CD4 T cell numbers were reduced
in the spleen and LN of tg6 mice. In addition, both CD8
T cell and B cell numbers were reduced in the spleen. In
contrast, dendritic cell and macrophage populations
were increased in LN of tg6 mice at late-stage EAE
(Additional file 2: Table S1). In the CNS at late-stage
EAE, except for an increase in CD8 T cell and macro-
phage numbers, the leukocyte populations in tg21 mice
were very comparable to those in wt mice. Crucially, in
tg21 mice no differences were observed in any of the
leukocyte populations in the periphery at any EAE stage
as compared to wt (Additional file 2: Table S1).
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In summary, the flow cytometry data shows that the cel-
lular immune response in tg6 mice differs from the re-
sponse in wt mice primarily in the periphery. In contrast,
leukocyte populations in tg21 mice do not differ from wt
mice in any of the peripheral organs. Finally, the changes
observed in macrophage and CD8 population in the CNS
of tg21 mice are not detected in tg6 mice.
rhEpo expression does not prevent myelin damage or
promote remyelination in EAE
Reduced EAE severity in tg6 and tg21 mice could be ex-
plained by an amending effect of rhEpo expression on
myelin damage, remyelination, or astrocyte activation.
Therefore, in a first approach, we performed Western
blot analysis of spinal cord lysates harvested from naïve
mice and animals at peak and late-stage EAE. In all
mice, myelin basic protein (MBP) expression, represent-
ing a proxy of myelin integrity, was diminished at peak
EAE followed by some recuperation at late stages
(Fig. 4b). At both peak and late EAE, the MBP levels in
transgenic and wt spinal cord lysates were comparable,
suggesting a similar scale of myelin loss and remyelina-
tion in both strains. In good agreement, luxol fast blue
histology of lumbar and thoracic spinal cord harvested
from mice at late-stage EAE also revealed a similar de-
gree of myelin damage in wt, tg6, and tg21 mice (Fig. 4a).
Thus, rhEpo expression does not significantly prevent
myelin damage or promote remyelination during EAE.
a
b
Fig. 2 Cytokine and chemokine expression profiles during EAE in wt, tg6, and tg21 mice. a Quantitative RT-PCR expression analysis of a broad
panel of cytokine mRNAs in spinal cord at different EAE stages in the various rhEpo-expressing mouse lines. n = 5 tg21, 5 tg6 and 10 wt, t test
versus peak wt **p < 0.001. b Multiplex analysis of cytokine and chemokine protein amounts in spinal cord lysates from wt, tg21 and tg6 mice at
late-stage EAE. n = 3, t test versus wt *p < 0.05
Moransard et al. Journal of Neuroinflammation  (2017) 14:202 Page 7 of 13
rhEpo expression limits neuronal loss in EAE
Neuroprotective properties have been attributed to ex-
ogenous Epo administration in several in vitro and in
vivo experimental models of neurodegeneration includ-
ing various EAE models [20, 30, 53, 54]. To investigate if
endogenous expression of rhEpo in the CNS confers
neuroprotection in EAE, we first performed Western
blot analysis of brain lysates harvested from naïve mice
and animals at peak and late-stage EAE. In all mice,
changes in pan-neurofilament (NF), phosphorylated
(smi35), and non-phosphorylated neurofilament (smi32)
expression, representing a proxy of neuronal integrity,
were significantly diminished at peak EAE followed by
some recuperation at late stages (Additional file 3: Fig-
ure S2). Notably, expression levels of these neurofila-
ment species were comparable between transgenic and
wt mice at all EAE stages.
The EAE model we used in this study is characterized
by extensive inflammation of the spinal cord rather than
inflammation of the brain. Therefore, we performed a
detailed immunohistochemical analysis and quantitation
on the cellular level of thoracic and lumbar spinal cord
of wt and tg21 mice (Fig. 5). Although pan-
neurofilament staining of lumbar and thoracic spinal
cords harvested from mice at late-stage EAE and subse-
quent quantitative image analysis shows loss of dorsal
funicular axons in both wt and tg21 mice, axonal loss
was significantly more extensive in wt animals (NF,
Fig. 5a, b). We also used anti-smi35 antibody that reacts
primarily with phosphorylated neurofilament H and M
and stains thick and thin axons and, albeit faintly, cell
bodies. Using this marker, comparable results were ob-
tained again revealing more extensive loss of dorsal fu-
nicular axons in wt mice (smi35, Fig. 5a, b). Importantly,
although neuronal loss in wt mice was more extensive,
co-staining with DAPI indicated a similar degree of
leukocyte infiltration in wt and tg21 mice (Inserts in
smi35 pictures of Fig. 5a). Smi32 immunohistochemistry
was used to assay the extent of axonal damage (smi32,
Fig. 5a). In contrast to smi35, smi32 stains mainly dam-
aged neurons by reacting with a non-phosphorylated
epitope in neurofilament H, which is masked by phos-
phorylation in healthy neurons. Surprisingly, quantitative
analysis revealed a comparable number of damaged
axons in wt and tg21 mice (smi32 Fig. 5a, b).
In summary, damaged axons were detected at late-stage
EAE in the spinal cord of both wt and tg21 mice; however,
axonal loss was significantly more prominent in wt animals.
Discussion
To date, several rodent studies have presented evidence
for a beneficial effect of exogenous Epo treatment in
EAE [25–27, 30–38]. However, the underlying mecha-
nisms by which its palliating effects are mediated remain
a matter of debate. Unfortunately, several human trials
have produced mixed results, most likely due to the
small and heterogeneous patient groups enrolled [40–
42]. Clearly better mechanistic insight into the beneficial
effect of Epo treatment in EAE may help determine the
best approach to treatment of MS patients with Epo (or
its derivatives). Using two transgenic mouse models that
either overexpress Epo systemically or limited to the
CNS, we show for the first time that prevention of neur-
onal loss in the spinal cord appears to be the primary





Fig. 3 Leukocyte populations at peak EAE in the CNS, spleen, and
inguinal lymph nodes of wt, tg6, and tg21 mice. Flow cytometric
analysis at peak EAE of a CNS-infiltrating leukocytes, b leukocytes in
the spleen, and c leukocytes in the inguinal lymph nodes (LN). For
gating strategy and definition of leukocyte populations see the
“Methods” section. n = 6 tg21, 6 tg6, and 12 wt. For all statistical
analysis, ANOVA versus wt. *Significance between wt and tg and #
between tg21 and tg6
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We and others [52] have observed significantly ele-
vated Epo mRNA levels in the spinal cord at peak dis-
ease, when leukocyte infiltration into the CNS is most
prominent and pro-inflammatory cytokine levels are
high. These levels slowly decrease at late-stage EAE co-
inciding with a decline in CNS-infiltrating leukocytes
and a shift to anti-inflammatory cytokine expression.
This timing strongly suggests that neuroinflammation
triggers these events and highlights an inherent protect-
ive response of the CNS to injury. This is further under-
lined by the fact that exogenously applied Epo [25, 26,
30–34, 36, 37] and overexpression of Epo as in this study
clearly benefits outcome by reducing disease severity.
Clearly, Epo-mediated suppression of the inflammatory
response in the periphery and/or CNS, altering the cellu-
lar immune response and cytokine/chemokine expres-
sion, could explain its beneficial effects. However, a
positive effect of Epo on neuroprotection/regeneration,
myelin protection, remyelination, or microglial responses
would explain the benefits equally well. Although global
rhEpo expression in tg6 mice modulates the peripheral
immune response, this effect does not appear to contrib-
ute significantly to improved EAE outcome because
modest rhEpo expression restricted to the CNS (tg21
mice) results in comparable disease alleviation without
altering the peripheral immune response. Direct periph-
eral effects of rhEpo in tg21 mice can be excluded as in-
creases in hematocrit, rhEpo in the blood, or changes in
the immune compartment were not detected under any
circumstances indicating that possible leakage of rhEpo
from the CNS due to blood-brain barrier breakdown did
not occur. As the EAE disease course was comparable in
both lines, a disease improvement mainly due to Epo-
mediated peripheral immunomodulation can be clearly
excluded.
Of all the CNS leukocyte populations assayed, apart
from an increase in CD8 T cells in tg21 mice at late-
stage EAE, only the macrophage population was affected
in transgenic animals compared to wt animals. However,
where tg21 mice showed a decrease in macrophages at
peak and an increase at late EAE as compared to wt, we
found the opposite result in tg6 animals with an increase
at peak and no significant difference at late-stage EAE.
Taken together, these results suggest that potential Epo-
triggered alterations in leukocyte population within the
CNS are unlikely to explain the beneficial effects of Epo
on EAE progression.
In summary, although various reports suggest Epo has
a direct effect on the immune response resulting in alle-
viation of disease, our study does not reproduce the de-
tails of these findings. For example, Li et al. observed a
reduction of spinal cord major histocompatibility com-
plex (MHC) class II expression in Epo-treated animals
that they correlated with reduced microglia activation
[33]. However, in all our mice, a comparable number of
microglia in the CNS at all EAE stages was seen arguing
a
b
Fig. 4 Myelin loss and remyelination in wt, tg6, and tg21 mice during EAE. a Luxol fast blue myelin staining of lumbar and thoracic spinal cord
from naïve wt mice and wt, tg21, and tg6 mice at late-stage EAE. Scale bar = 200 μm. b Representative Western blot analysis of CNS lysates from
2 naïve and 2 EAE diseased tg21, tg6 and wt mice for myelin basic protein (MBP). Reduced intensity of MBP bands at peak EAE indicates myelin
loss, whereas the increase in intensity at late-stage EAE indicates remyelination
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against a major effect of Epo on microglia activation.
Similarly, we did not detect any changes in regulatory
T cells in our mice, in contrast to a report showing
Epo can promote expansion of regulatory T cell pop-
ulations [32]. It is notable however that all these pre-
vious works used exogenous short-duration Epo
therapies whereas this study used a constitutively
overexpression of Epo.
In addition to changes in the cellular immune re-
sponse, several observations in tg6 mice on the cyto-
kine/chemokine level are notable. For example, IL-23
mRNA is significantly elevated in the CNS of naïve tg6
a
b
Fig. 5 Neuronal loss in the spinal cords of wt, tg6, and tg21 mice at late-stage EAE. a Immunohistochemical analysis of lumbar and thoracic spinal
cord sections for neurofilament (NF), non-phosphorylated neurofilament H (smi32), and phosphorylated neurofilament H and M (smi35). Inserts in
smi35 panels show DAPI co-stain revealing leukocyte infiltration into the spinal cord. Scale bar = 200 μm (b) Quantitative analysis of immunohis-
tochemistry shown in a. NF: wt n = 4, tg21 n = 3; smi32: wt n = 3, tg21 n = 3; smi35: wt n = 4, tg21 n = 4. Four sections per animal from lumbar
and thoracic spinal cord were analyzed. t test versus wt *p < 0.05, **p < 0.01
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mice indicating that constitutively high CNS Epo levels
trigger IL-23 expression. How Epo triggers IL-23 expres-
sion, and in which cells, is at present unclear. Indeed, it
is remarkable that the elevated IL-23 mRNA amounts in
tg6 mice have no additional exacerbating effect since IL-
23 is an essential cytokine in EAE development promot-
ing the expansion of pathogenic myelin-specific IL-17 T
cells (reviewed in [55–57]). Similarly, although signifi-
cantly lower IL-2 mRNA levels were found in the CNS
of tg6 mice, and thus lower CNS-infiltrating T cell num-
bers were anticipated, the cellular immune response in
the CNS proved comparable between strains. These co-
nundrums suggest the possibility that other cytokines
such as IL-9 or IL-15 compensate for the reduced IL-2
amounts. Indeed, multiplex showed IL-9 levels were ele-
vated in tg6 mice. It is still debated whether IL-9 con-
tributes positively [58] or negatively [59, 60] to the
pathogenesis of EAE; however, our data suggests that
high IL-9 levels do not exacerbate disease score or in-
crease the number of leukocytes in the CNS. Overall, it
appears that Epo-mediated immunomodulation does not
significantly impact disease outcome.
Our data indicates that Epo mediates its positive effects
in EAE predominantly by neuroprotection in the spinal
cord, particularly by preventing neuronal loss but not ne-
cessarily inhibiting neuronal damage. Indeed Epo has a
well-established neuroprotective role in a number of dis-
ease paradigms including neonatal or adult rodent focal
brain ischemia, brain trauma, and spinal cord injury
(reviewed by [22]). Generally, Epo protects neuronal cells
by regulating the balance between proapoptotic and antia-
poptotic pathways. In agreement, we noted significantly in-
duced levels of the proapoptotic protein Bax in wt animals
were suppressed in the transgenic lines (data not shown)
showing a tipping of the balance towards protection in the
Epo-overexpressing animals. However, a whole array of
protective mechanisms is likely to be activated as suggested
by a number of reports [20, 53, 54, 61–63]. As we cannot
exclude the possibility that permanent overexpression of
EPO in the brain might lead to physiological adaptive
changes that are undetected in our study, further investiga-
tion is needed to fully understand Epo’s neuroprotective
mechanism of action during EAE progression.
Although putative regeneration-enhancing effects are
less well studied in vivo, a few reports have implicated
Epo may promote the production of neuronal and oligo-
dendrocyte progenitors [25, 64, 65] and improve recov-
ery of neurological function [66]. Neurogenesis was not
investigated in this study and so cannot be excluded, but
our data surprisingly shows that myelin damage at late-
stage EAE is not significantly different between wt and
transgenic mice. This suggests that Epo does not ameli-
orate EAE through prevention of myelin damage, or
augmentation of remyelination.
Interestingly, our data and that of others [52] indicate that
the CNS inherently responds to neuroinflammation with an
increase in locally produced Epo, which possibly serves as a
neuroprotective mechanism. The data presented herein fur-
ther underlines that a relatively modest increase in CNS
Epo, in addition to the endogenous increase in response to
neuroinflammation, could significantly enhance this neuro-
protective effect to obtain maximum palliation. Several
groups in academia and the pharmaceutical industry have
explored CNS-specific Epo receptor agonists that have no,
or low, efficacy for peripheral Epo receptors to avoid indu-
cing elevated hematocrit levels [16, 67, 68]. Undoubtedly,
such agents would provide invaluable benefit for the treat-
ment of CNS disorders. An alternative approach could be to
locally increase Epo levels in the CNS. For example, astro-
cytes are likely to be largely responsible for the increase in
CNS Epo levels in response to neuroinflammation. Identifi-
cation of a pathway that triggers astrocytic Epo production
could be used to develop therapeutic approaches that in-
crease CNS Epo without increasing Epo levels in the periph-
ery. Such an approach would avoid side effects on the
peripheral immune system and circumvent detrimental in-
creases in hematocrit. Notably, the lack of a phenotype in
unchallenged tg21 mice suggests that modest constitutive
overexpression of Epo in the CNS would be well tolerated.
Conclusions
This study demonstrates that the primary beneficial effect
of Epo on EAE disease progression resides in the CNS.
Despite the extensively investigated effects of Epo on the
immune system, our data indicates that the neuroprotective
effects of Epo treatment in EAE are sufficient to provide
maximum alleviation. Notably, only a moderate increase of
Epo levels in the CNS was required for a positive outcome.
With these insights, this study advocates that use of Epo
(and neuroprotective derivatives of Epo) as a future thera-
peutic for neurological disease should not be dismissed.
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